Industry Focus
Healthcare: Why Investors Just Doubled Their Money on This Stock
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:15:17
- Mas informaciones
Informações:
Sinopsis
Alexion Pharmaceuticals is paying $8.4 billion to buy Synageva, a company without any sales, so Fool analyst Michael Douglass and contributor Todd Campbell are digging into this deal to see what it may mean to biotech investors.
